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Cancer is a disease at the cellular level involving heritable disorders in cellular control mechanism.
Cancer cells also need to adapt their metabolism to survive and multiply under the metabolically
compromised conditions provided by the tumor microenvironment. Tumor cells alter their metabolism
to maintain unregulated cellular proliferation and survival, but this transformation leaves them reliant
on constant supply of nutrients and energy. They alter their metabolism to support their rapid prolif-
eration and expansion across the body. After the discovery of based on the altered cancer cell metabolism
in 1930, loads of studies have shed light on several aspects of cancer metabolism with a common goal to
ﬁnd new ways for effectively eliminating tumor cells by targeting their energy metabolism. Research has
directed most of its resources to elucidate the causes, prevention and possible cure for cancer, yet the
process has been elusive claiming human lives more than ever. This disease is a manifestation of etio-
logical and pathological disturbances of mechanisms that control cell division, differentiation and
metabolism. 50% of all human tumors carry genetic alterations that lead to the inactivation of some
tumor suppressor proteins. Cancer cells are shown to experience characteristic changes in their meta-
bolic programs, including increased uptake of glucose, enhanced rates of glutaminolysis and fatty acids
synthesis, suggesting that metabolic shifts supports tumor cells growth and survival. In this review, we
summarized the major concepts of glucose metabolization and explore the molecular basis of aerobic
glycolysis of cancer cells.
© 2017 Turkish Society of Medical Oncology. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There has been an enigmatic search of information on the
mechanism of cancer related metabolic adaptations, and this has
resulted in accumulated evidences suggesting considerable asso-
ciation between several pathways in human metabolism and ma-
lignant transformation.1e3 Carcinogenesis is a complex, multistep
process requiring the elimination of several cell-imposed barriers
such as anti-proliferative responses, programmed cell death-
inducing mechanisms, and senescence. This occurs mostly
through genetic alterations in oncogenes and tumor suppressor
genes.4 In other for the body to prevent the growth of tumor, there
is chronic activation of the immune system. These two processes
(tumor growth and immune system activation) are responsible forsilvernonferous@gmail.com
ty of Medical Oncology.
ogy. Production and hosting by Elan increased energy usage and thus for continuous consumption of
energetic substrates, such as carbohydrate.5 In fact, the oxidation of
glucose into CO2 and H2O through the citric acid cycle is a well-
known major source of energy and plays a key role in the biosyn-
thesis of ATP, constituent of DNA, RNA and phospholipids. Glucose
is also necessary for the pentose phosphate pathway and the syn-
thesis of reducing compounds such as NADPH. Energy metabolism
in advanced tumor cells is severely compromised by the occurrence
during the disease progression of symptoms such as nausea
anorexia, and vomiting, which does not allow normal nutrition and
therefore, a regular supply of carbohydrates, proteins, amino acids
and vitamins. Reduced oral intake resulting from anorexia or
obstruction of the gastrointestinal tract plays a crucial role in the
development of the cancer cachexia syndrome. In addition to the
reduced food intake, important changes of energy metabolism and
biochemical/metabolic abnormalities in carbohydrate, protein and
lipid biochemistry andmetabolism have been observed, whichmay
account for cancer-related anorexia/cachexia syndrome.6 Altered
energy metabolism consisting of increased resting energy expen-
diture associated with increased metabolism of sugar, lipid andsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
A. Fadaka et al. / Journal of Oncological Sciences 3 (2017) 45e5146protein metabolism are typical of cancer cells. These changes are a
consequence of alterations in intermediary metabolism (carbohy-
drate, protein, and lipids) associated with cancer. Also, activation of
oncogenes and deactivation of tumor suppressor genes, have been
associated to cancer-associated metabolic remodeling of epigenetic
marks.7
2. Overview of carbohydrate metabolism in normal cell
Carbohydrates constitute a major part of our diet and our food is
the ultimate source of all the sugars that enter our metabolic
pathways. About two-thirds of dietary carbohydrate is the plant
polysaccharide. Disaccharides such as lactose and sucrose and
some other polysaccharides like cellulose are also a part of our food,
but our intake of free monosaccharide like glucose, fructose and
galactose is relatively reduced.8
Carbohydrate metabolism starts with digestion in the small
intestine when monosaccharides are absorbed into the blood
stream. Blood sugar concentrations are controlled by three hor-
mones: insulin, glucagon, and epinephrine. If the concentration of
glucose in the blood is increased insulin is released from the
pancreas. Insulin stimulates the transfer of glucose into the cells in
the liver andmuscles, in the liver andmusclesmost of the glucose is
converted to glycogen, a process known as glycogenesis. Glycogen
is stored in the liver and muscle. The breakdown of glycogen to
glucose is called glycogenolysis. The metabolites from glycolysis
form links with protein, lipid and nucleic acid. Glucose is the central
molecule in carbohydrate breakdown and synthesis. All major
pathways of carbohydrate metabolism are connected to conver-
sions of glucose, since glucose is the main sugar in the blood and
the main energy fuel in the body. The metabolic pathways are
glycolysis, Oxidation of Pyruvate, Citric Acid Cycle, Pentose Phos-
phate Pathway, Glycogen metabolism (glycogenolysis, glycogen-
esis) and Gluconeogenesis.
2.1. Glycolysis (Embden-Meyerhoff pathway) in normal cells
Glycolysis is a universal pathway for catabolism of glucose in
animals and plants. It occurs in all cells of our body. The process
(glycolysis) convert one molecule of glucose to two molecules of
pyruvic acid, and the energy released is conserved in the form of
ATP and reducing equivalent NADH. The main function or aim of
glycolysis is to provide energy and intermediates for other meta-
bolic pathways. The major sources of glucose for glycolysis are di-
etary carbohydrates and cellular glycogen. Glucose undergoes
glycolysis by a sequence of 10 cytosolic reactions, seven of which
are reversible while three are irreversible. The ﬁrst ﬁve reactions
constitute the “investment” phase since they use ATP, while the last
ﬁve reactions constitute the “pay-off” phase and yield ATP. In
glycolysis (normal cells), which happens in the cytoplasm, one
glucose molecule yields 2 ATPs and 2 NADH molecules (NADH is
another energy-carrying molecule), and two pyruvates. If oxygen is
present, the two pyruvates, with help from the pyruvate dehy-
drogenase enzyme complex, is converted to two Acetyl-CoA mol-
ecules. The acetyl-CoAs enter the mitochondrion where it fuels the
citric acid cycle. Each acetyl-CoA molecule goes through the citric
acid cycle. Therefore, from one glucose, the yield is 6 NADH mol-
ecules, two FADH2 molecules, and two ATP molecules. The 6
NADH þ2 FADH, plus the NADH produced in glycolysis and at the
PDH complex, nowenter the “electron transport system” (ETS). This
is where the efﬁcient production of ATP occurs: The ETS is a multi-
stage process, called oxidative phosphorylation or cellular respi-
ration, which, with the help of ATP synthase has the following
yield: This summary gives a theoretical yield of 40 ATP per glucose.
32e38 ATPs are generated depending on the enzymes anindividual's DNA codes for. Cancer cells typically “switch” from
“cellular respiration” to the very inefﬁcient glycolysis for their ATP
needs, a phenomenon described by Otto Warburg in 1924. The
amazing thing is that tumors, which are highly energy demanding
tissues, switch to a very inefﬁcient energy producing pathway. They
make up for this energy demand by going through glycolysis faster
than necessary in normal cells.
2.2. Metabolizing pathways in cancer
Cancer is a disease condition arising from uncontrolled division
of cells in the body to form lumps of tissues called tumors. There are
many different types of cell in the body, andmany different types of
cancer which arise from different types of cell. Some are more
easily treated than others, particularly if diagnosed at an early
stage, some have a better outlook (prognosis) than others.9 These
cells may invade or spread to other parts of the body where they
can go on proliferating and causing unhealthy condition to the
system. Those cells with minimum uncontrolled growth and do not
invade other cells are said to be benign while cells that grow and
divide rapidly and as well invade other tissues are said to be
malignant.
Normally, cells are expected to grow, divide and then die. In a
situation where the deoxyribonucleic acid (DNA) of a cell is
damaged by some factors, known as risk factors, and the cell cannot
repair the damaged DNA, then it may not be able to control the
normal programmed cell growth. This results to development of
cancer. In each case, it is important to know exactly what type of
cancer has developed, how large it has become, whether it has
spread, and how well it usually responds to treatment. Cancer re-
sults from the development of abnormal properties in normal cells
that enable them to grow excessively and spread to other locations.
This abnormal development can be caused by mutations that occur
from factors such as paints, chemicals, radiation, ultraviolet light
and chromosome replication errors.10 Thesemutagens alter DNA by
changing nucleotide bases and can even change the shape of DNA.
The altered DNA produces errors in DNA replication, as well as
errors in protein synthesis. These changes inﬂuence cell growth,
cell division, and aging. Viruses such as Human papilloma virus can
cause cancer by altering cell genes though a class of cancer. Cancer
viruses change cells by integrating their genetic material with the
host cell's DNA.
2.2.1. The Crabtree effect
Crabtree made an observation on the utility of carbohydrates by
cancer cells.11 It was observed that, for normal cells, the presence of
glucose slightly increased respiration or had no effect on oxygen
consumption. On the contrary, glucose decreased oxygen uptake by
cancer cells. This respiratory inhibition is known the Crabtree ef-
fect. It is now known that this metabolic transformation of cancer
cells is not a speciﬁc feature of carcinogenesis, but appears to be a
requirement of rapidly dividing cells such as proliferating he-
matopoietic progenitor cells, spermatozoa, intestinal mucosal cells,
renal cells, and embryonic stem (ES) cells.12 This phenomenon is
also reported in bacteria and yeast. Apart from rapid proliferation,
an important characteristic shared by all these cells, as will be ex-
pected from respiratory impairment, is increased glycolysis.
Another observation of the Crabtree effect is the initial increase in
respiration following the provision of glucose. Indeed, it appears
that other hexoses can induce this effect in cancer cells as well.
Several explanations have been provided based of the Crabtree
effect, although the molecular mechanism is not fully understood.
The mechanisms are as follows: (1) Competition for available
ADP þ Pi between oxidative phosphorylation and glycolysis can
cause respiratory abnormalities by increased glucose availability.13
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inhibition of oxidative enzymes. (3) Disruption of coupled respi-
ration by calcium; increased mitochondrial calcium levels by
glucose caused an increased association of the inhibitory subunits
of F1F0 to the ATP synthase to inhibit coupled respiration.12 (4)
Glucose metabolism increases reactive oxygen species production
that damages mitochondrial membranes and depresses respiration
(Fig. 2).14 (5) The Crabtree effect might be regulated by several
mechanisms in cancer cells, involving changes in ATP/ADP ratio, Pi,
glucose-6-phosphate, cytosolic pH among others.15 Irrespective of
the mechanism, cancer cells are glycolytic and this is associated
with partial mitochondrial impairment (i.e., suppressed respira-
tion, less oxygen consumption, and low ATP production). Series of
reactions that produce pyruvate is known as glycolysis. Under
anaerobic conditions, glycolysis produces minimal energy in the
form of ATP. This mode of glycolysis is not coupled to the TCA cycle
and oxidative phosphorylation. However, under aerobic conditions,
glycolysis, TCA cycle activity, and oxidative phosphorylation
generate considerable energy for cellular functions. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and the mitochondrial
phosphate carrier (PiC) compete for the free cytoplasmic inorganic
phosphate pool (Pi). A similar competition for free ADP occurs
between the mitochondrial adenine nucleotide translocase (ANT)
and two of the glycolysis enzymes: Phosphoglycerate kinase (PGK)
and pyruvate kinase (PK). Fructose 1,6-biphosphate inhibits the
mitochondrial respiratory complexes III and IV. Increased calcium
(Ca2þ) accumulation in the mitochondrial matrix lead to the inhi-
bition of the ATP synthase.16
2.2.2. The Warburg phenomenon
While it can be conceived that fast-growing cancer cells will
require more energy than normal cells, it is ironic to realize that, in
contrast to normal cells, cancer cells use a primitive inefﬁcient re-
action, aerobic glycolysis, to generate considerable amounts of their
energy. A possible reason for this bioenergetic alteration is the
requirement to produce other metabolic end products to support
their rapid growth and proliferation under low oxygen tension, and
the possible adaptation to evade death in toxic environments or
because of cytotoxic agents. Probably the most important treatise
ever provided for mitochondrial dysfunction and its possible
causative role of cancer is that provided several decades ago by the
Nobel Laureate and Biochemist, Otto Warburg. In his series of ex-
periments on respiration and metabolism of cancer cells, coupled
with his in-depth analysis of reported works from other in-
vestigators at the time, by an approach reminiscent of whatWatson
and Crick employed in deciphering the DNA double helical struc-
ture, OttoWarburg could unwaveringly hypothesize that neoplastic
transformation originated because of irreversible damage to
mitochondrial respiration. Cancer cells are, therefore, compelled to
rely on the inefﬁcient glycolytic mode of ATP synthesis (2 ATPs/
glucose), rather than respiration that produces substantially more
ATP/glucose (approximately 36 ATPs/glucose). Warburg observed
that, in conditions of normal oxygen tension, normal cells produced
most of their energy via mitochondrial respiration. In contrast, over
50% of cancer cell energy was generated in the cytosol via glycol-
ysis, with the remainder from the mitochondrial respiratory chain.
This bioenergetically inefﬁcient glycolytic reliance of cancer cells
for most of their energy production is not primarily due to lack of
oxygen, because it operates even in the presence of adequate
oxygenation. The bioenergetically inferior nature of glycolysis im-
plies that cancer cells must adopt a mode of increased glucose
import to meet their energy demands. The mechanisms of aerobic
glycolysis (Warburg effect) of cancer cells. Glucose transporters
(Glut1 and Glut3) in the plasma membrane are overexpressed.
Hexokinase isoform II (HK II) interacts with mitochondria throughthe voltage-dependent anionic channel (VDAC). Phosphofructoki-
nase (PFK) is overactive because the predominance of its L- and P-
isoforms. An overexpressed PFKB3 maintains higher levels of
fructose 2,6-biphosphate that further activate PFK. The M2 isoform
of pyruvate kinase (PK) regulates the glycolytic ﬂux and promotes
metabolite accumulation to fulﬁll the biosynthetic needs of the cell.
The M-isoform of lactate dehydrogenase (LDH) is overexpressed.
Pyruvate transport into the mitochondrial matrix through its spe-
ciﬁc carrier (PC) is decreased. Pyruvate dehydrogenase complex is
inhibited in a phosphorylation-dependent mechanismmediated by
an over-expressed pyruvate dehydrogenase kinase (PDHK). Muta-
tions in succinate dehydrogenase (SDH) impair its activity. The
levels of the mitochondrial respiratory complexes I, III and IV are
decreased. Mitochondria ATP synthase activity is restricted by the
overexpression of its inhibitory subunit.16
2.2.3. Differences between cancer cells and normal cells
Cancer cells differ from normal cells in many ways that allow
them to grow out of control and become invasive. One important
difference is that cancer cells are less specialized than normal
cells.17 This is one reason that, unlike normal cells, cancer cells
continue to divide uncontrollably. In addition, cancer cells can
ignore signals that normally tell cells to stop dividing or that begin a
process known as programmed cell death, or apoptosis, which the
body uses to get rid of unneeded cells by producing large quantity
of CD47. Cancer cells may be able to inﬂuence the normal cells,
molecules and blood vessels that surround and feed a tumor (an
area known as the micro-environment).10 For example, cancer cells
can induce nearby normal cells to form blood vessels that supply
tumors with oxygen and nutrients, which they need to grow
(Fig. 1). Cancer cells are also often able to evade the immune sys-
tem, a network of organs, tissues, and specialized cells that protects
the body from infections and other conditions. Although the im-
mune system normally removes damaged or abnormal cells from
the body, some cancer cells can “hide” from the immune system.18
Cancer cells exhibit aerobic glycolysis. This means that cancer cells
derive most of their energy from glycolysis that is glucose is con-
verted to lactate for energy followed by lactate fermentation, even
when oxygen is available. This is termed the Warburg effect. This
produces far less energy than oxidative phosphorylation and as
cancer cells require a lot of energy to grow this seems paradoxical.
The Warburg effect may be beneﬁcial to cancer cells however
because it provides precursors for many biosynthetic pathways.
These precursors include amino acid precursors and NADPH and
ribose sugars for DNA and RNA synthesis. The Warburg effect may
be caused by impaired oxygen sensing in cancer cells or by the Myc
transcription factor which is unregulated in cancer cells. Myc by-
passes the normal oxygen sensing mechanism and results in acti-
vation of transcription of glycolytic enzymes. Glycolytic enzymes
such as GLUT1, lactate dehydrogenase, pyruvate kinase and the
lactate exporter are unregulated in cancer cells whilst pyruvate
dehydrogenase is inhibited leading to increased glycolytic ﬂux and
impaired ability of pyruvate to enter oxidative phosphorylation.
3. The effects of hypoxia on glucose utilization in tumors
The availability of growth regulating factors control normal cell
proliferation in tissues and by the interaction with surrounding
cells. Nutrients and oxygen availability, necessary for cell prolifer-
ation and metabolism, largely depends on blood supply. Initial tu-
mor growth occurs in the absence of formation of new blood
vessels. Tumor cells bypass environmental growth-controlling
constraints (Fig. 2). This is achieved by acquiring the ability to
proliferate independently of growth signals, though, for example,
mutations in receptor-associated signaling molecules, and by
Fig. 1. Schematic diagram of aerobic glycolysis in cancer cell compared with normal cell.
Fig. 2. Glycolysis in tumor cell. (Allosteric regulations of glycolysis confer metabolic plasticity with respect to local pO2).
A. Fadaka et al. / Journal of Oncological Sciences 3 (2017) 45e5148becoming insensitive to antigrowth stimuli, such as thosemediated
by cell-to-cell contacts. In the early carcinogenesis phase, uncon-
trolled cell proliferationmoves tumor cells away from blood vessels
and, therefore, from oxygen and nutrient supply. The only way
oxygen and glucose can reach the inner cells of a non-vascularized
tumor is by diffusion across the basement membrane and through
the peripheral tumor-cell layers. However, partial oxygen pressuredrops to very low values 100 mm away from blood vessels.3.1. Tumor fuel metabolism
The main metabolic pathways that contribute to malignancy
and offer potential drug targets are illustrated. Metabolic enzymes
that have been associated with tumor initiation and growth are
A. Fadaka et al. / Journal of Oncological Sciences 3 (2017) 45e51 49marked in red. GLUT1, glucose transporter; HK, hexokinase; 6PGD,
6-Phosphogluconate dehydrogenase; PFKFB 3,6-phosphofructo-2-
kinase; GAPDH, Glyceraldehyde3-phosphatedehydrogenase;
PHGDH, phosphoglycerate dehydrogenase; PGAM1, Phosphogly-
ceratemutase1; PKM, Pyruvate kinase; LDHA, lactated hydrogenase
A; MCT, Monocarboxylate transporter; PDH, Pyruvate dehydroge-
nase; CPT1, Carnitine palmitoyl transferase I; FASN, fatty acid syn-
thase; RNR, ribonucleotide reductase; FH, fumarate hydratase;
SDH, succinate dehydrogenase; IDH, isocitrate dehydrogenase;
GLUD, glutamate dehydrogenase; GLS1, glutaminase1; ASCT2,
Amino-acid transporter2; ACLY, ATP citrate lyase; ACC, acetyl-
CoAcarboxylase; ACSS2, Acetyl CoA synthetase 2; DHFR, DHF
reductase; TYMS, thymidylate synthase; HMGCR, HMG-CoA
reductase; CK, choline kinase; G6P, glucose-6-phosphate; F6P,
fructose-6-phosphate; PRPP, 5-phospho-alpha-D-ribose1-
diphosphate; IMP, inosine monophosphate; UMP, uridine mono-
phosphate; dNTP, deoxynucleotide triphosphate; G3P, glyceralde-
hyde3-phosphate; 3PG, 3-phosphoglycerate; 2PG, 2-
phosphoglycerate; PEP, phosphoenol pyruvate; OAA, Oxaloace-
tate; AKG, a-ketoglutarate; HMG-CoA, 3-hydroxy-3-methyl-glu-
taryl coenzymeA; THF, tetrahydrofolate; 5, 10mTHF, 5, 10-
methylenetetrahydrofolate; DHF, dihydrofolate.19 Hypoxia and
glucose shortage are rapidly generated in the inner mass of a
growing tumor. Paradoxically, however, it is known since the
1920s.20 that tumor cells have a much higher rate of glucose con-
sumption through a glycolysis pathway that prevent pyruvate from
entering the Krebs cycle and converts pyruvate to lactate: the so-
called Warburg effect.1 In fact, many tumors use this glucose to
lactate pathway even in the presence of oxygen, and therefore, the
term aerobic glycolysis is often used as a substitute to the Warburg
effect. It is important to note that the glycolytic switch occurring in
cancer cells is not necessarily accompanied by a reduction in
oxidative phosphorylation.21 Nowadays, the augmented glycolytic
activity of tumors is clinically exploited by positron emission to-
mography for the identiﬁcation of metastatic lesions. This tech-
nique takes advantage of the increased ability of tumor cells to take
up and metabolize glucose compared with normal tissues.10 It can
therefore be stated that hypoxia is what drives tumor cells to fuel
glucose in a non-oxidative ‘glucose to lactate’ pathway. However, it
is currently believed that the glycolytic switch is acquired very early
in carcinogenesis even before tumors experience hypoxia.1 Conse-
quently, the fact that, even in normoxic conditions, many tumors
use aerobic glycolysis for their metabolic requirements indicates
that the Warburg effect has functions that are not solely limited to
hypoxia adaptation.
3.2. Cancer cell adaptation to hypoxic conditions
The transcription factor hypoxia-inducible factor-1 (HIF-1) is a
key regulator responsible for the induction of genes that facilitate
adaptation and survival of cells and the whole organism from
normoxia ð 21% O2) to hypoxia ( 1% O2).22,23 Since the identiﬁ-
cation of HIF, knowledge has grown exponentially. Because of the
realization that hypoxia has a strong impact, via gene expression,
on cell biology and mammalian physiology. HIF-1 is a pleiotropic
transcription factor that regulates genes involved in the hypoxia
induced metabolic switch, regulation of tumor pH, and angiogen-
esis.24 The high glycolytic rate characteristic of hypoxic solid tumor
is due in part to the greatly increased expression of hexokinase II
(HK II),25 a known transcriptional target of HIF-1. Hexokinase ca-
talyses the ﬁrst step in the glycolytic pathway where glucose is
phosphorylated to glucose-6-phosphate with conversion of one
ATP to ADP. There are four isoforms encoded by the mammalian
genomes that are usually expressed at low levels in cells.26 By
increasing the expression level of HK II, hypoxia via HIF-1, cantherefore modulate glucose metabolism. HK II has additional fea-
tures that are relevant in the context of cancer-cell apoptosis. HK II
is normally associated with voltage-dependent anion channel
(VDAC).27 A 30kDa pore protein inserted in the outer mitochondrial
membrane that regulates the transport of metabolites in and out of
the mitochondrial inter-membrane space.28 Mitochondria are key
components of the apoptotic cell death process. Upon exposure to
cell-death stimuli, mitochondria release cytochrome-c and other
apoptogenic factors into the cytoplasm where they trigger caspase
activation and apoptosis.29 Although the exact mechanism by
which this happens remains unclear. One model proposes that Bax,
once activated by death stimuli, cooperates with VDAC to form a
large cytochrome-c conducting channel through the mitochondrial
membrane.30 It can be envisioned that a protein interacting with
VDAC, like HK II, has the potential to prevent the interaction of
proapoptotic proteins with mitochondria and consequently inter-
fere with apoptosis. Therefore, in hypoxic tumors, the initial over-
expression of HK II as a primary adaptation to hypoxia may
secondarily confer resistance to apoptosis. Supporting this notion is
the observation that disruption of the binding of HK II to mito-
chondria, through activation of GSK3b and phosphorylation of
VDAC, potentiates chemotherapy induced cytotoxicity in trans-
formed cells.31 Moreover, methyl jasmonate, an anticancer agent
that interacts directly with mitochondria can induce apoptosis
selectively in cancer cells apparently by detaching hexokinases
from mitochondria.32 Recently, it has also been shown that the
release of HK II from mitochondria potentiates cisplatin-induced
cytotoxicity.33 Current evidence indicates that hypoxia response
in cancer cells, in addition to modulating glucose metabolism,
renders them more resistant to death stimuli. Hypoxic tumors
remain invasive and metastatic.34 The best-characterized regula-
tory mechanism is that modulating HIF-1a’s stability. Under well-
oxygenated normoxic conditions, prolyl hydroxylation (by prolyl
hydroxylases (PHDs)) and subsequent ubiquitination (by von-
Hippel Lindau (VHL)-containing E3 ubiquitin-protein ligase) of
the oxygen-dependent degradation (ODD) domain of HIF-1a leads
to rapid degradation of HIF-1a with a half-life of 5e8 min. Conse-
quently, HIF-1 is inactive under normoxic conditions.35e37 On the
other hand, under oxygen-deprived hypoxic conditions, HIF-1a
becomes stable because oxygen depletion directly decreases the
PHDs' activity.36 Then, HIF-1a interacts with HIF-1b, forms a het-
erodimer, HIF-1,22 binds to its cognate DNA sequence, the hypoxic-
responsive element (HRE), and ﬁnally induces the expression of
various genes related to angiogenesis, metastasis, glycolysis.38e40 In
addition to the regulation of HIF-1a’s stability, another post-
translational modiﬁcation of HIF-1a is known to function in the
regulation of the transactivational activity of HIF-1. Under normoxic
conditions, factor inhibiting HIF-1 (FIH-1) becomes active and hy-
droxylates an asparagine residue of HIF-1a.35,37 The asparaginyl
hydroxylation blocks the interaction of HIF-1a with the transcrip-
tional co-factor p300 and CBP, resulting in the suppression of HIF-
1's transactivational activity. Because oxygen is a substrate of FIH-1
as well as PHDs, HIF-1's transactivational activity is restored under
oxygen-deprived hypoxic conditions.41
3.3. The effect of tumor microenvironment on the tumor
metabolism
Low oxygen concentration within solid tumors because of
abnormal blood vessel formation, defective blood perfusion, and
unlimited cancer cell proliferation is referred to as hypoxia. As tu-
mor growth outpaces that of adequate vasculature, oxygen and
nutrient delivery become insufﬁcient. This dynamic interplay be-
tween the normal stroma and the malignant parenchyma, coupled
with inevitable hypoxia, is common in any solid tumor
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transformed cells create the tumor microenvironment (TME). The
progression of hypoxia over time is a consequence of increased
oxygen consumption by abnormally proliferating cancer cells,
which also produce an acidic environment. Most human tumors are
highly heterogeneous and involve diverse microenvironments. A
typical microenvironment seen in solid tumors is hypoxia, low-
oxygen conditions under physiological level.42 Tumor hypoxia is a
concern in cancer therapy because it increases the metastatic and
angiogenic potential of cancer cells,38,43 and can render cancer cells
resistant to radiation and chemotherapy.44 Apart from malignant
cells, the TME contains cells of the immune system, the tumor
vasculature and lymphatics, as well as ﬁbroblasts, pericytes and
sometimes adipocytes, which are discussed in detail below. These
cells are frequently distinguished by cell-type-speciﬁc markers,
which are often cell surface molecules. The tumor microenviron-
ment is a complex scaffold of an extracellular matrix (ECM) and
various cell types. In addition to malignant cells, vascular cells,
stromal cells and immune cells are common cellular residents of
the tumor niche. Tumor cells mould this environment for their own
needs via intercellular communication pathways, such as direct
cell-to-cell contacts and the release of growth factors, matrix
metalloproteases, ECM proteins and extracellular vesicles (EVs).
Tumor cell-mediated stromal modiﬁcations include: suppression of
anti-tumoural immune responses, deposition and degradation of
ECM components, induction of vascular network formation and
recruitment of stromal cells and tumor-promoting immune cells. In
turn, heterogeneous tumor microenvironmental components
create a favorable environment for tumor growth and dissemina-
tion. Various tumor microenvironmental stressors are inherent
features of solid tumors that profoundly modify the tumor milieu
and accelerate tumor progression towards malignancy.45
4. Conclusion
Cancer cells under hypoxic conditions have been recognized as
crucial and excellent targets for cancer therapy because they
mediate tumor malignancy and resistance to conventional treat-
ments and seen in malignant tumors, not in normal tissues.
Countless approaches have been used as targets; hypoxia-targeting
using hypoxia-responsive promoters and hypoxia-speciﬁc replica-
tion of adenovirus as well as hypoxic cytotoxins and HIF-1 in-
hibitors. Hypoxia/HIF-1-targeting gene therapy is a promising
tumor-speciﬁc approach with few side effects in normal tissues,
and has the potential to enhance the effect of radiation therapy.
Some approaches are now in clinical trials and are expected to lead
to breakthroughs in cancer therapy. The elucidation of how a
metabolism change with important genes and enzyme mutation
causes cancer will liberate future novel cancer treatment devel-
opment. Also, the manipulation of glucose metabolism with the
immune system should also be subject of intense interest to
ameliorate cancer progression.
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